Selected article for: "case severe and mortality rate"

Author: Chu, Helen Y.; Renaud, Christian; Ficken, Elle; Thomson, Blythe; Kuypers, Jane; Englund, Janet A.
Title: Respiratory Tract Infections Due to Human Metapneumovirus in Immunocompromised Children
  • Document date: 2014_10_21
  • ID: ujvbm6ae_22
    Snippet: Similar retrospective studies performed in pediatric cancer patients have looked at morbidity and mortality related to other respiratory viruses. Parainfluenza virus was associated with LRTI in 20-36% of patients with a mortality rate of 0-7% in a mixed population of pediatric cancer and transplant patients [14, 15] . Similarly, respiratory syncytial virus (RSV) has been associated with LRTI in 28% and mortality in 8% of a mixed group of pediatri.....
    Document: Similar retrospective studies performed in pediatric cancer patients have looked at morbidity and mortality related to other respiratory viruses. Parainfluenza virus was associated with LRTI in 20-36% of patients with a mortality rate of 0-7% in a mixed population of pediatric cancer and transplant patients [14, 15] . Similarly, respiratory syncytial virus (RSV) has been associated with LRTI in 28% and mortality in 8% of a mixed group of pediatric and transplant patients [16] . More recently, pandemic H1N1 and seasonal influenza A were associated with LRTI rates of 20-42% and 4-27% and mortality rates of 10-12% and 2-4%, respectively, despite treatment of the majority of patients with antiviral drugs [17, 18] . An additional study performed in a larger group of patients described a lower rate of LRTI (16%) associated with pandemic H1N1 with only 1 severe case, with no related mortality [19] . Prospective studies of hMPV in adults with hematologic malignancies demonstrated that 9% of respiratory tract infections were attributed to hMPV, and that the majority of these were in HSCT recipients [13] .

    Search related documents:
    Co phrase search for related documents
    • additional study and cancer patient: 1
    • additional study and large group: 1
    • additional study and low rate: 1, 2, 3, 4
    • additional study and mixed population: 1, 2
    • additional study and mortality morbidity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • additional study and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • additional study and Parainfluenza virus: 1, 2, 3, 4
    • antiviral drug and hematologic malignancy: 1, 2, 3
    • antiviral drug and large group: 1, 2, 3
    • antiviral drug and low rate: 1, 2, 3, 4, 5, 6
    • antiviral drug and mortality morbidity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral drug and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral drug and Parainfluenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • cancer patient and hematologic malignancy: 1, 2, 3
    • cancer patient and large group: 1
    • cancer patient and low rate: 1, 2, 3, 4, 5, 6, 7, 8
    • cancer patient and mortality morbidity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cancer patient and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • hematologic malignancy and hmpv prospective study: 1